ClinicalTrials.gg

Homozygous Familial Hypercholesterolemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 68 studies for Homozygous Familial Hypercholesterolemia across more than 10 countries. 13 are recruiting or about to start. 59 of them are mainly about Homozygous Familial Hypercholesterolemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
42
Recruiting
12
Terminated
4
Active, not recruiting
4
Withdrawn
3
Status unknown
2

Phase

Phase 3
31
Phase 2
20
Phase 1
2
Early Phase 1
1

Where

United States
36
Canada
28
Netherlands
25
South Africa
19
Italy
15
France
13

Who develops what

Add Homozygous Familial Hypercholesterolemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Arrowhead Pharmaceuticals, CSPC Pharmaceutical Group and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zodasiran☆ Track2 live phase-3 studies: NCT07473843, NCT07037771Arrowhead Pharmaceuticals
VSA003☆ Track1 live phase-3 study: NCT06712771Visirna Therapeutics HK Limited

The 2 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Aug 2027 est.zodasiran · Arrowhead Pharmaceuticals · Phase 3 main aimNCT07037771 A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) — primary endpoint: Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period) · 70 enrolled
  • 16 Sept 2027 est.SYH2070 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07591298 Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia — primary endpoint: The percentage change in serum LDL-C level from baseline · 18 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Homozygous Familial Hypercholesterolemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PCSK9 inhibitors 6 · Statins 3

Coming up

6studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger. 8 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 12
AgeWomenMen
105 (42%)5 (42%)
1810 (83%)10 (83%)
309 (75%)9 (75%)
409 (75%)9 (75%)
509 (75%)9 (75%)
658 (67%)8 (67%)
758 (67%)8 (67%)
857 (58%)7 (58%)

Across all 68 studies, recruiting or not: 22% stop at 75 or younger and 19% at 65; 56% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Homozygous Familial Hypercholesterolemia studies take

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 322 mo16–34 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 68. Browse all 68 → or search them.